🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great #ASCO25 discussion by ⁦Anant Madabhushi⁩ around AI based prediction models in #HNCA ⁦Winship Cancer Institute of Emory University⁩ ⁦Emory University⁩ ⁦ASCO⁩ ⁦MedAI Emory⁩

Congratulations to Sagar Lonial, MD, Jane Meisel, MD and Kevin Kalinsky, MD, MS, for being named fellows of ASCO! They received their awards today during a presentation at #ASCO25. 🏅

🔎Zanzalintinib +Nivo +/- Relatlimab in untreated ccRCC? STELLAR002 ✅Doublet therapy shows activity in untreated metastatic ccRCC (CR 8%, ORR 63%, PFS 18.5m) ✅Acceptable tolerability ✖️Addition of rela did not improve ORR or mPFS ASCO @oncoalert @Oncolive Targeted Oncology

Radiation oncologist Patricia Santos, MD, MS, shares insights on her poster highlighting “Access to cancer care for undocumented immigrants in the United States.” #ASCO25

Winship thoracic oncologists Jennifer Carlisle, MD, and Fatemeh Ardeshir, MD, presented their work during today’s afternoon poster session. Dr. Carlisle discussed the use of tarlatamab for SCLC in the outpatient setting and Dr. Ardeshir covered ctDNA in young-onset NSCLC. #ASCO25

📣 Good morning! Day 3 is underway at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting in Chicago. Find a full listing of presentations with Winship experts here. 👉 brnw.ch/21wSZut

Winship breast oncologist Kevin Kalinsky, MD, MS, presented an oral abstract on the “Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE” this morning. #ASCO25

Winship SVP of Cancer Nursing Colleen Lewis, MSN, ANP-BC, AOCNP, stopped by our #ASCO25 booth to share insights on the growing role of patient navigation in cancer care.

🔎Avelumab +Sacituzumab Govitecan vs Avelumab mono therapy as 1L maintenance treatment in advanced urothelial carcinoma w/o progression? Interim analysis from JAVELIN Bladder Medley ✅Maintenance avelumab + saci improved PFS 11.17m> avelumab mono therapy 3.75m (HR 0.49) ✅PFS

Winship radiation oncologist Zachary Buchwald, MD, PhD, provides a brief description of a fascinating clinical trial evaluating how time-of-day–specified immunotherapy for patients with advanced melanoma affects their outcome. #ASCO25

Excellent presentation by ⁦Conor Steuer⁩ covering reversal of immunosuppressive environment with #pepinemab in #HNCA ASCO CSS ⁦Winship Cancer Institute of Emory University⁩ ⁦Emory University⁩ ⁦Gregory Lesinski⁩ Vaccinex⁩ ⁦Schmitt Lab⁩

🔎Exploratory analyses of HRRm by gene subgroup and associations with efficacy from TALAPRO2? ✅ Cohort 2 of TALAPRO2 shows improved rPFS and OS in mCRPC and HRRd with talazoparib + enza vs enza monotherapy ➡️ Most pronounced in BRCA1/2 and CDK12 Limitations: retrospective

Good morning from Chicago! 📣 Winship at #ASCO25 Monday Sessions 📣 View Full Schedule ➡️ brnw.ch/21wT5xe

Hey there, #ASCO25 attendee! We can't wait to see you at Booth 14041 before the expo closes. We have lots to share - #IMS25, workshops, membership, and more!

It was a great experience and is a wonderful journal.

Emory hematology and medical oncology fellow Maroun Bou Zerdan, MD, is presenting his work, “Prognostic relevance of Aurora kinase A (AURKA) expression in prostate cancer” in this morning’s #ASCO25 poster session.

Winship medical oncologist Jacob Berchuck, MD, shares a brief summary of a study, “Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in metastatic castration-resistant #prostatecancer” from today’s #ASCO25 poster session.

Winship medical oncologist Jacqueline Brown, MD, gives a summary of an abstract discussion she moderated at #ASCO25 on new treatment directions in advanced #bladdercancer.

Winship breast oncologist Jane Meisel, MD, summarizes yesterday’s #ASCO25 plenary session of the SERENA-6 trial results showing the benefit of using circulating tumor DNA (ctDNA) monitoring to guide treatment changes for patients with HR+/HER2- advanced #breastcancer.

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: Natalie Callander ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm ECOG-ACRIN Cancer Research Group #NCT03937635 Vincent Rajkumar @mweissmdphd